Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Diamant Thaçi"'
Autor:
Bruce, Strober, Diamant, Thaçi, Howard, Sofen, Leon, Kircik, Kenneth B, Gordon, Peter, Foley, Phoebe, Rich, Carle, Paul, Jerry, Bagel, Elizabeth, Colston, John, Throup, Sudeep, Kundu, Chitra, Sekaran, Misti, Linaberry, Subhashis, Banerjee, Kim A, Papp
Publikováno v:
Journal of the American Academy of Dermatology. 88:40-51
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits cytokine signaling in psoriasis pathogenesis.The objective of this study was to demonstrate deucravacitinib superiority versus placebo and apremilast in moderate to
Autor:
T. Werfel, F Abeck, Sonja Ständer, Diamant Thaçi, A Langenbruch, Jochen Schmitt, Nicole Mohr, S. Weidinger, Matthias Augustin
Publikováno v:
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
With AtopicHealth1, the first national care study on atopic dermatitis (AD) was conducted in 2010. At that time, about one third of the patients undergoing treatment by dermatologists showed severe limitations in quality of life, which indicated an i
Autor:
Richard B, Warren, Michael, Gold, Melinda, Gooderham, Leon H, Kircik, Jean-Philippe, Lacour, Philip, Laws, Monika, Liljedahl, Charles, Lynde, Marie Holst, Mørch, Wiebke, Sondermann, Diamant, Thaçi
Publikováno v:
Journal of Drugs in Dermatology. 20:436-441
Psoriasis is a chronic disease requiring long-term treatment strategies. Optimal strategies should include initial rapid relief of symptoms followed by long-term management to maintain remission. This 4-week open-label phase of a long-term proactive
Autor:
Meng Zhang, Brad Shumel, Faisal A. Khokhar, Zafer E. Ozturk, Lisa A. Beck, Diamant Thaçi, Mette Deleuran, Marjolein S. de Bruin-Weller, Zhen Chen
Publikováno v:
Beck, L A, Thaçi, D, Deleuran, M, de Bruin-Weller, M, Chen, Z, Khokhar, F A, Zhang, M, Ozturk, Z E & Shumel, B 2022, ' Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis : results from an open-label extension study ', Journal of Dermatological Treatment, vol. 33, no. 3, pp. 1608-1616 . https://doi.org/10.1080/09546634.2020.1871463
BACKGROUND: Most systemic agents used for moderate-to-severe atopic dermatitis (AD) may lead to adverse events requiring routine laboratory monitoring, increasing patient burden and possibly decreasing treatment adherence.OBJECTIVE: To evaluate clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c67e84b9721182b828b18a88e61ee9b
https://pure.au.dk/portal/da/publications/laboratory-safety-of-dupilumab-for-up-to-3-years-in-adults-with-moderatetosevere-atopic-dermatitis(7fe39251-db3f-47a2-9c82-30d768712c56).html
https://pure.au.dk/portal/da/publications/laboratory-safety-of-dupilumab-for-up-to-3-years-in-adults-with-moderatetosevere-atopic-dermatitis(7fe39251-db3f-47a2-9c82-30d768712c56).html
Autor:
T. Bieber, Margaret Gamalo, Fabio P. Nunes, Norito Katoh, Diamant Thaçi, Maher Issa, Kristian Reich, Dennis Brinker, Jamie Weisman, Eric L. Simpson, E. Riedl, Antonio Torrelo, M S de Bruin-Weller, Jacob P. Thyssen, Robert Bissonnette, Katrin Holzwarth, Melinda Gooderham, Jonathan Janes
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 35:476-485
Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in la
Autor:
F Brock, Yves Poulin, Alice B. Gottlieb, Richard B. Warren, Andrew Blauvelt, M Boehnlein, C. Leonardi, Kenneth B. Gordon, Kristian Reich, Diamant Thaçi, C Ecoffet
Publikováno v:
British Journal of Dermatology. 184:652-662
Background Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic. Objectives To report the 3-year efficacy of CZP in plaque psoriasis, pooled from the CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) phase III tria
Autor:
Kim Papp, Joseph Wu, Peter Nash, Wolf-Henning Boehncke, Joseph F. Merola, M-A Hsu, Jordi Gratacós, Daniela Graham, Cunshan Wang, P. Young, Diamant Thaçi
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820
Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 12 (2020) pp. 2809-2820
Background Psoriatic arthritis (PsA) is a chronic, systemic immune‐mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the trea
Autor:
Neil M.H. Graham, Joel M. Gelfand, Mette Deleuran, Chen Wang, Abhijit Gadkari, Peter Foley, Diamant Thaçi, John D. Davis, Marie L A Schuttelaar, Kristian Reich, Jean-David Bouaziz, Heribert Staudinger, Michihiro Hide, Zhen Chen, Bolanle Akinlade, Andrew Blauvelt, Iftikhar Hussain, Marjolein S. de Bruin-Weller, Weily Soong, Robert Bissonnette, Marius Ardeleanu, Gianluca Pirozzi, Lisa A. Beck, Laurent Eckert, Manoj Rajadhyaksha, Lawrence Sher, Seth Forman
Publikováno v:
Deleuran, M, Thaçi, D, Beck, L A, de Bruin-Weller, M, Blauvelt, A, Forman, S, Bissonnette, R, Reich, K, Soong, W, Hussain, I, Foley, P, Hide, M, Bouaziz, J D, Gelfand, J M, Sher, L, Schuttelaar, M L A, Wang, C, Chen, Z, Akinlade, B, Gadkari, A, Eckert, L, Davis, J D, Rajadhyaksha, M, Staudinger, H, Graham, N M H, Pirozzi, G & Ardeleanu, M 2020, ' Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study ', Journal of the American Academy of Dermatology, vol. 82, no. 2, pp. 377-388 . https://doi.org/10.1016/j.jaad.2019.07.074
Journal of the American Academy of Dermatology, 82(2), 377-388. MOSBY-ELSEVIER
Journal of the American Academy of Dermatology, 82(2), 377-388. MOSBY-ELSEVIER
Background: Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD).Objective: To assess the long-term safety and efficacy of dupilumab in patients with AD.Methods: This ongoing, multicenter, open-label exte
Autor:
Eric L. Simpson, Carle Paul, Jeremias Antinew, Hernan Valdez, Ricardo Rojo, Bimal Malhotra, Thomas Bieber, Jacek Zdybski, Jonathan I. Silverberg, Andrew Pink, Marco DiBonaventura, Pinaki Biswas, Chia-Yu Chu, Seth Forman, Ileana A. Ionita, Rodney Sinclair, Diamant Thaçi, Yoko Kataoka, Fan Zhang
Publikováno v:
Immunotherapy. 14(1)
Atopic dermatitis (AD, also called atopic eczema) is a long-term skin disease that causes intensely itchy, red skin. Healthcare providers can prescribe medicated creams and ointments to reduce the signs and symptoms of AD. However, these treatments a
Autor:
Pedro Herranz, Gaëlle Bégo-Le Bagousse, Marjolein S. de Bruin-Weller, Brad Shumel, Dimittri Delevry, Jashin J. Wu, April W. Armstrong, Gil Yosipovitch, Raymond Zhang, Diamant Thaçi, Ana B. Rossi, Jingdong Chao
Publikováno v:
Dermatology and Therapy
Introduction Atopic dermatitis (AD) can have a profound negative impact on the quality of life (QoL) of patients. We analyzed the long-term changes in AD symptoms, QoL, and patient assessment of treatment effect in adults with moderate-to-severe AD t